GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Suzhou Zelgen Biopharmaceuticals Co Ltd (SHSE:688266) » Definitions » Capital Expenditure

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Capital Expenditure : ¥-82.17 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Suzhou Zelgen Biopharmaceuticals Co Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Suzhou Zelgen Biopharmaceuticals Co's cash flow for capital expenditures for the three months ended in Jun. 2024 was ¥-20.5 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Jun. 2024 was ¥-82.17 Mil.

Suzhou Zelgen Biopharmaceuticals Co Capital Expenditure Historical Data

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Zelgen Biopharmaceuticals Co Capital Expenditure Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial -15.11 -57.68 -70.74 -88.62 -62.60

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.71 -11.71 -19.78 -30.23 -20.45

Suzhou Zelgen Biopharmaceuticals Co Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-82.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suzhou Zelgen Biopharmaceuticals Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Suzhou Zelgen Biopharmaceuticals Co Ltd (SHSE:688266) » Definitions » Capital Expenditure
Comparable Companies
SZSE:300255 SZSE:002287 SHSE:688443 SZSE:301047 SHSE:688105 SHSE:605116 SHSE:688062 SZSE:002030 SHSE:688076 SHSE:600201 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN
Website
http://www.zelgen.com
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
Executives
Zhang Bin Core technical personnel
Huang Gang senior management
Lv Bin Hua Directors, senior managers, core technical personn
Lu Hui Ping Directors, senior managers
Gao Qing Ping senior management
Wu Ji Sheng Directors, senior managers, core technical personn
Zhang Jun Li senior management
Wu Li Qing Core technical personnel
Core technical personnel
Sheng Ze Lin Directors, senior managers, core technical personn

Suzhou Zelgen Biopharmaceuticals Co Headlines

No Headlines